Investment Rating - The report assigns a "Buy" rating for the company, indicating that the stock is expected to outperform the benchmark index by more than 20% over the next 12 months [5][15]. Core Insights - The company's revenue for the first three quarters of 2024 reached approximately 521 million yuan, representing a year-on-year growth of 87.05%. The net profit attributable to the parent company was about 245 million yuan, up 182.65% year-on-year [2][3]. - The rapid growth of the non-COVID respiratory product series is highlighted, with revenue from this segment accounting for approximately 84.83% in 2023 and increasing to 97.74% in the first half of 2024. This segment includes various testing kits for respiratory pathogens [2][3]. - The company has been expanding its overseas market presence, recently obtaining product approvals in Malaysia and Myanmar, which is expected to accelerate revenue growth from international markets [2][3]. Summary by Sections Financial Performance - For the first three quarters of 2024, the gross margin, net profit margin, and net profit margin after deducting non-recurring items were 81.0%, 47.0%, and 43.0%, respectively, showing increases of 9.35, 15.88, and 19.27 percentage points year-on-year [2]. - The company forecasts revenues of 782 million yuan, 943 million yuan, and 1.119 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 356 million yuan, 463 million yuan, and 567 million yuan [3][4]. Market Outlook - The respiratory pathogen testing market is in a rapid growth phase, and the company is positioned as a leading player in this sector, expected to benefit from industry expansion [3]. - The report anticipates that the company's overseas business will become a new growth engine as more product qualifications are approved [2][3].

证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-013 | --- | --- | |---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 动类别 | 特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 ☑路演活动 现场参观 □其他（券商策略会） | | 参与单位名称 及人员姓名 | 三头牛基金：林伟杰；嘉强私募：王子帅；银国达资本：梁志安；明勤基 金：朱一平； ...

证券代码：688253 证券简称：英诺特 公告编号：2024-056 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 118.6052 | | 累计已回购股数占总股本比例 | 0.8692% | | 累计已回购金额 | 5,001.26 万元 | | 实际回购价格区间 | 35.93 元/股~45.37 元/股 | 一、 回购股份的基本情况 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-055 北京英诺特生物技术股份有限公司关于认购私募基 金份额暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1 / 2 市公司重大资产重组管理办法》规定的重大资产重组。减资完成后，泓创海河出 资额合计为 20,613.00 万元，景达广源认缴出资 1,250.00 万元，认缴出资占基金 总认缴出资额的比例降低至 6.06%。 三、其他事项 一、对外投资暨关联交易概述 北京英诺特生物技术股份有限公司（以下简称"公司"）于 2023 年 11 月 30 日召开第二届董事会第二次会议、第二届监事会第二次会议，同意公司之全资子 公司北京景达广源科技发展有限公司（以下简称"景达广源"）作为天津泓创海 河创业投资合伙企业（有限合伙）（以下简称"泓创海河"）之有限合伙人，以自 有资金认缴出资人民币 2,000.00 万元，出资比例占基金总认缴出资额的 11.80%。 具 体 内 容 详 见 公 司 于 2023 年 12 月 2 日 在 上 海 证 券 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights steady improvement in market penetration and anticipates significant growth in both domestic and overseas markets in the fourth quarter [1] - The company reported a total revenue of 521 million yuan for the third quarter, representing an increase of 87.05%, with a net profit attributable to the parent company of 245 million yuan, up 182.65% [1] - The report emphasizes that the profit growth rate significantly outpaces revenue growth, with a notable increase in core revenue driven by the rise in respiratory multi-detection products [1] Summary by Sections Financial Performance - For the third quarter, the company achieved a revenue of 521 million yuan, with a net profit of 245 million yuan, and a non-recurring net profit of 224 million yuan, reflecting increases of 87.05%, 182.65%, and 239.12% respectively [1] - The company’s core revenue showed a rapid growth trend, with a year-on-year increase of 250% [5] Future Outlook - The third quarter is viewed as a turning point for annual revenue, with expectations for rapid growth in the fourth quarter driven by increased demand for respiratory multi-detection products [1] - The company has received approvals for two multi-detection products in Malaysia and Myanmar, which cover 15 types of respiratory pathogens, indicating strong potential for market expansion [1] Financial Projections - The company is projected to achieve revenue growth rates of 67.8%, 41.7%, and 34.6% for the years 2024, 2025, and 2026 respectively, with net profits expected to reach 396 million yuan, 569 million yuan, and 758 million yuan in the same years [5][6] - The report forecasts an increase in gross margin from 76.0% in 2023 to 88.3% in 2024, indicating improved profitability [5]

北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688253 证券简称：英诺特 公告编号：2024-054 截至 2024 年 10 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式回购公司股份 350,385 股，占公司总股本 136,458,196 股的比例为 0.2568%， 回购成交的最高价为 42.00 元/股，最低价为 35.93 元/股，支付的资金总额为人民 币 14,438,551.17 元（不含印花税、交易佣金等交易费用）。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 北京英诺特生物技术股份有限公司董事会 2024 年 11 月 4 日 | 回购方案首次披露日 | ...

Financial Performance - Total operating income for the first three quarters of 2024 reached 520,820,403.02 RMB, a significant increase from 278,434,984.25 RMB in the same period of 2023[17] - Net profit for the first three quarters of 2024 was 244,605,662.28 RMB, a substantial rise from 86,539,519.51 RMB in the same period of 2023[19] - Comprehensive income for the first three quarters of 2024 reached 241,113,891.70 RMB, an increase of 87,844,399.88 RMB compared to the same period last year[20] - Basic and diluted earnings per share for the first three quarters of 2024 were both 1.80 RMB, up from 0.64 RMB in the same period last year[20] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were 247,200,900.72 RMB, compared to 172,676,941.47 RMB in the same period of 2023[18] - R&D expenses increased to 60,987,843.21 RMB in the first three quarters of 2024, up from 34,402,685.84 RMB in the same period of 2023[18] - Sales expenses rose to 55,547,509.40 RMB in the first three quarters of 2024, compared to 32,632,554.07 RMB in the same period of 2023[18] Liabilities and Equity - Contract liabilities increased to 100,655,839.49 RMB in 2024, up from 32,461,122.42 RMB in the previous year[15] - Total liabilities for 2024 were 223,646,680.00 RMB, compared to 126,424,020.97 RMB in the previous year[16] - Total equity attributable to the parent company's shareholders increased to 2,043,709,845.59 RMB in 2024, up from 1,842,008,497.63 RMB in the previous year[16] - Total assets and liabilities combined reached 2,065,655,177.63 RMB in 2024, up from 2,170,133,866.56 RMB in the previous year[16] Cash Flow - Cash received from sales of goods and services in the first three quarters of 2024 was 509,770,329.71 RMB, a significant increase from 219,325,256.10 RMB in the same period last year[20] - Cash flow from operating activities for the first three quarters of 2024 was 214,181,071.15 RMB, compared to 41,519,953.07 RMB in the same period last year[21] - Cash flow from investing activities for the first three quarters of 2024 was 216,791,661.90 RMB, a significant improvement from -221,164,887.41 RMB in the same period last year[21] - Cash and cash equivalents at the end of the third quarter of 2024 were 543,759,840.18 RMB, compared to 155,972,119.66 RMB at the end of the same period last year[22] - The company received 3,499,300,811.67 RMB from investment recoveries in the first three quarters of 2024, up from 2,536,782,393.51 RMB in the same period last year[21] - The company paid 54,424,326.40 RMB in dividends, profits, or interest payments in the first three quarters of 2024, compared to 24,394,958.16 RMB in the same period last year[22] - The company's cash outflow for purchasing goods and accepting services in the first three quarters of 2024 was 92,135,917.78 RMB, up from 74,993,688.59 RMB in the same period last year[20] - The company's cash outflow for employee compensation and benefits in the first three quarters of 2024 was 72,165,183.38 RMB, compared to 56,038,966.51 RMB in the same period last year[21] Other Comprehensive Income - Other comprehensive income after tax for the first three quarters of 2024 was -3,491,770.58 RMB, compared to 1,304,880.37 RMB in the same period of 2023[19]

证券代码：688253 证券简称：英诺特 公告编号：2024-053 北京英诺特生物技术股份有限公司关于召开 2024 年 半年度暨第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京英诺特生物技术股份有限公司（以下简称"公司"）已公开发布公司 2024 年半年度报告，并将于 2024 年 10 月 26 日发布 2024 年第三季度报告，为便于广 大投资者更全面深入地了解公司经营成果、财务状况，公司计划于 2024 年 11 月 1 日（星期五）下午 15:00-16:00 举行 2024 年半年度暨第三季度业绩说明会，就 投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年半年度、2024 年第三季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 1 / 3 会议召开时间：2024 年 11 月 1 日（星期五）下午 15:00-16:00 会议召开地点： 上 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-052 北京英诺特生物技术股份有限公司关于公司及子公 司近期获得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1 / 2 力及核心竞争力。 三、风险提示 上述产品的实际销售受到市场需求、市场竞争以及公司市场推广效果等多种 因素影响，利润贡献具有不确定性，尚无法预测上述产品对公司未来经营业绩的 影响。敬请广大投资者谨慎投资、注意投资风险。 特此公告。 北京英诺特生物技术股份有限公司董事会 一、公司及子公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称"公司"）全资子公司英诺特 （唐山）生物技术有限公司（以下简称"唐山英诺特"）近期新取得产品资质 4 项，具体情况如下表所示： | 序 | 获批主 | 产品名称 | | 注册证号（备 | 发证日期 | 有效期至 | | --- | --- | --- | --- | --- | --- | --- | | 号 | 体 | | | 案号） | | | | | （1）马来西亚产品 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-051 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 2.59 | | 累计已回购股数占总股本比例 | 0.0190% | | 累计已回购金额 | 93.30 万元 | | 实际回购价格区间 | 35.93 元/股~36.00 元/股 | 一、 回购股份的基本情况 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自 ...